Clonal Hematopoiesis of Indeterminate Potential Linked to CVD Risk
Add Drugs.com as a trusted source on Google to see more of our health news and information in your Google Search results.
- Tap the button to open Google's source settings.
- Tick the box next to Drugs.com.
- You can change it anytime in your Google settings.
Requires a signed-in Google account.
FRIDAY, Jan. 9, 2026 -- For patients with primary solid tumors receiving cancer therapy, clonal hematopoiesis of indeterminate potential (CHIP) is associated with an increased risk for cardiovascular disease (CVD), according to a study published online Jan. 8 in JAMA Oncology.
Derek Shyr, Ph.D., from the University of Alabama at Birmingham, and colleagues examined the association between CHIP and CVD risk among patients with primary solid tumors who received chemotherapy, radiotherapy, or immunotherapy in a cohort study. Electronic health records were linked to whole-genome sequencing data from 250,038 participants from 2006 to 2025.
The study included 8,004 eligible participants with a primary solid tumor diagnosis; 549 (6.9 percent) had CHIP. The researchers found that compared with those without CHIP, participants with CHIP had a significantly higher 10-year cumulative incidence of heart failure (20.3 versus 14.5 percent) and ischemic CVD (25.3 versus 18.5 percent) in the propensity score-matched cohort. CHIP was associated with an increased risk for heart failure in adjusted Fine-Gray models (subdistribution hazard ratio, 1.26). There was a significant interaction between CHIP and intensive chemotherapy cycles (seven cycles or more) on heart failure risk in an exploratory 24-month landmark analysis (subdistribution hazard ratio, 1.02).
"These findings support the potential clinical utility of CHIP testing for cardiovascular risk stratification for patients with solid tumors undergoing cancer treatment and suggest that incorporating CHIP status may improve cardio-oncology treatment of cancer survivors," the authors write.
Several authors disclosed ties to the biopharmaceutical industry; the sequencing was funded by the Alliance for Genomic Discovery, consisting of NashBio, Illumina, and industry partners.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2026 HealthDay. All rights reserved.
Read this next
Universal Germline Testing IDs Hereditary Risk in Late-Onset Tumors
THURSDAY, Oct. 15, 2026 -- Universal germline testing identifies pathogenic variants in patients with early-, average-, and late-onset cancer across 32 solid tumor types...
County-Level Variation Seen in Cardiovascular Disease Mortality
THURSDAY, Oct. 15, 2026 -- From 2000 to 2019, there was a decrease in overall cardiovascular disease (CVD) mortality, with wide variation among U.S. counties, according to a study...
American Society for Radiation Oncology, Sept. 26-30
The annual meeting of the American Society for Radiation Oncology was held from Sept. 26 to 30 in Boston, and gathered physicians, oncology nurses, radiation therapists...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Drugs.com Podcast
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
